Viridian Therapeutics, Inc.\DE (VRDN) Cash from Operations (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Cash from Operations history runs 14 years deep, the most recent figure standing at 119654000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 29.14% year-over-year to 119654000.0 in Q1 2026; TTM through Mar 2026 was 303392000.0, a 8.45% decrease from a year earlier, with the FY2025 full-year figure at 276391000.0, down 18.97% from the prior year.
• Cash from Operations retreated to 119654000.0 in Q1 2026 per VRDN's latest filing, from 23754000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 18086000.0 in Q2 2022 and bottomed at 119654000.0 in Q1 2026.
• The 5-year median for Cash from Operations is 45223000.0 (2024), against an average of 53316000.0.
• Across the five-year window, Cash from Operations slumped 194.52% in 2023 and surged 67.61% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 34042000.0 in 2022, then dropped by 11.63% to 38000000.0 in 2023, then plunged by 92.98% to 73332000.0 in 2024, then jumped by 67.61% to 23754000.0 in 2025, then sank by 403.72% to 119654000.0 in 2026.
• Per Business Quant, the three latest VRDN Cash from Operations figures stand at 119654000.0 (Q1 2026), 23754000.0 (Q4 2025), and 84611000.0 (Q3 2025).